Figure 2. Competing risk estimators (inverse probability of treatment and censoring weighted risk ratios) for the effect of sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) vs glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) on primary cardiovascular and mortality outcomes (as‐treated analyses).

CVD indicates cardiovascular disease; HF, heart failure; HHF, hospitalization for HF; MACE, major adverse cardiovascular outcome; and MI, myocardial infarction.